. 2023 Apr 30;35(2):140–162. doi: 10.21147/j.issn.1000-9604.2023.02.05

Table 2. Stratification analysis of ALKBH5 gene polymorphisms with neuroblastoma susceptibility.

Variables	rs1378602 (cases/controls)		Adjusted OR^a (95% CI)	P^a	rs8400 (cases/controls)		Adjusted OR^a (95% CI)	P^a	Risk genotypes (cases/controls)		Adjusted OR^a (95% CI)	P^a
Variables	GG	GA/AA	Adjusted OR^a (95% CI)	P^a	GG/GA	AA	Adjusted OR^a (95% CI)	P^a	0	1−2	Adjusted OR^a (95% CI)	P^a
OR, odds ratio; 95% CI, 95% confidence interval; ^a, Adjusted for age and gender.
Age (month)
≤18	308/594	72/141	0.99 (0.72−1.36)	0.946	299/607	81/128	1.29 (0.94−1.76)	0.114	258/519	122/216	1.14 (0.87−1.49)	0.334
>18	477/905	110/173	1.19 (0.92−1.56)	0.189	464/886	123/192	1.22 (0.95−1.57)	0.125	397/785	190/293	1.27 (1.02−1.58)	0.033
Sex
Female	353/628	84/146	1.04 (0.77−1.40)	0.797	346/633	91/141	1.17 (0.87−1.58)	0.286	292/543	145/231	1.17 (0.91−1.50)	0.227
Male	432/871	98/168	1.18 (0.89−1.55)	0.251	417/860	113/179	1.30 (1.00−1.69)	0.050	363/761	167/278	1.26 (1.00−1.58)	0.049
Sites of origin
Adrenal gland	212/1,499	48/314	1.10 (0.79−1.54)	0.573	206/1,493	54/320	1.23 (0.89−1.69)	0.217	180/1,304	80/509	1.15 (0.87−1.53)	0.333
Retroperitoneal	279/1,499	64/314	1.12 (0.83−1.50)	0.477	273/1,493	70/320	1.20 (0.90−1.60)	0.225	229/1,304	114/509	1.29 (1.00−1.65)	0.046
Mediastinum	193/1,499	41/314	0.99 (0.69−1.42)	0.959	179/1,493	55/320	1.43 (1.03−1.98)	0.034	160/1,304	74/509	1.17 (0.87−1.57)	0.311
Others	90/1,499	28/314	1.45 (0.93−2.25)	0.101	96/1,493	22/320	1.07 (0.66−1.72)	0.791	78/1,304	40/509	1.30 (0.87−1.93)	0.197
Clinical stages
I+II+4s	400/1,499	98/314	1.12 (0.87−1.44)	0.377	398/1,493	110/320	1.29 (1.01−1.64)	0.041	337/1,304	171/509	1.29 (1.04−1.59)	0.018
III+IV	344/1,499	78/314	1.12 (0.85−1.48)	0.419	333/1,493	89/320	1.25 (0.96−1.63)	0.097	290/1,304	132/509	1.18 (0.94−1.49)	0.155